GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004312218 | Oral cavity | OSCC | regulation of I-kappaB kinase/NF-kappaB signaling | 155/7305 | 249/18723 | 7.79e-14 | 4.14e-12 | 155 |
GO:004312310 | Oral cavity | OSCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 122/7305 | 186/18723 | 1.68e-13 | 8.52e-12 | 122 |
GO:000724910 | Oral cavity | OSCC | I-kappaB kinase/NF-kappaB signaling | 169/7305 | 281/18723 | 4.69e-13 | 2.25e-11 | 169 |
GO:007190010 | Oral cavity | OSCC | regulation of protein serine/threonine kinase activity | 201/7305 | 359/18723 | 3.90e-11 | 1.27e-09 | 201 |
GO:00434054 | Oral cavity | OSCC | regulation of MAP kinase activity | 101/7305 | 177/18723 | 8.13e-07 | 1.12e-05 | 101 |
GO:00510907 | Oral cavity | OSCC | regulation of DNA-binding transcription factor activity | 221/7305 | 440/18723 | 9.06e-07 | 1.23e-05 | 221 |
GO:004586016 | Oral cavity | OSCC | positive regulation of protein kinase activity | 194/7305 | 386/18723 | 3.90e-06 | 4.59e-05 | 194 |
GO:003367418 | Oral cavity | OSCC | positive regulation of kinase activity | 228/7305 | 467/18723 | 8.31e-06 | 8.90e-05 | 228 |
GO:00719028 | Oral cavity | OSCC | positive regulation of protein serine/threonine kinase activity | 107/7305 | 200/18723 | 2.12e-05 | 2.02e-04 | 107 |
GO:00510917 | Oral cavity | OSCC | positive regulation of DNA-binding transcription factor activity | 134/7305 | 260/18723 | 2.52e-05 | 2.35e-04 | 134 |
GO:000941018 | Oral cavity | OSCC | response to xenobiotic stimulus | 222/7305 | 462/18723 | 4.00e-05 | 3.48e-04 | 222 |
GO:00510925 | Oral cavity | OSCC | positive regulation of NF-kappaB transcription factor activity | 82/7305 | 152/18723 | 1.28e-04 | 9.13e-04 | 82 |
GO:00321037 | Oral cavity | OSCC | positive regulation of response to external stimulus | 203/7305 | 427/18723 | 1.79e-04 | 1.22e-03 | 203 |
GO:005090010 | Oral cavity | OSCC | leukocyte migration | 176/7305 | 369/18723 | 3.80e-04 | 2.31e-03 | 176 |
GO:00603269 | Oral cavity | OSCC | cell chemotaxis | 146/7305 | 310/18723 | 2.13e-03 | 9.80e-03 | 146 |
GO:00305959 | Oral cavity | OSCC | leukocyte chemotaxis | 110/7305 | 230/18723 | 3.86e-03 | 1.58e-02 | 110 |
GO:00434062 | Oral cavity | OSCC | positive regulation of MAP kinase activity | 58/7305 | 112/18723 | 4.01e-03 | 1.64e-02 | 58 |
GO:00434107 | Oral cavity | OSCC | positive regulation of MAPK cascade | 213/7305 | 480/18723 | 8.71e-03 | 3.16e-02 | 213 |
GO:007162110 | Oral cavity | OSCC | granulocyte chemotaxis | 62/7305 | 125/18723 | 1.02e-02 | 3.52e-02 | 62 |
GO:00313495 | Oral cavity | OSCC | positive regulation of defense response | 127/7305 | 278/18723 | 1.32e-02 | 4.39e-02 | 127 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
S100A12 | insertion | Nonsense_Mutation | novel | c.129_130insCAGGTCAAGCCTTGTTAATTCCAGGGTGGTTCATG | p.Thr44GlnfsTer6 | p.T44Qfs*6 | P80511 | protein_coding | | | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
S100A12 | insertion | Frame_Shift_Ins | novel | c.118_119insTCCTTTGCTTCCCTCTCTCAATAACTCACTTAAGGCTCTACTC | p.Glu40ValfsTer26 | p.E40Vfs*26 | P80511 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
S100A12 | SNV | Missense_Mutation | rs761048858 | c.208G>A | p.Asp70Asn | p.D70N | P80511 | protein_coding | tolerated(0.43) | benign(0.006) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
S100A12 | SNV | Missense_Mutation | | c.146A>C | p.Lys49Thr | p.K49T | P80511 | protein_coding | deleterious(0.01) | possibly_damaging(0.848) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
S100A12 | SNV | Missense_Mutation | novel | c.105N>T | p.Gln35His | p.Q35H | P80511 | protein_coding | tolerated(0.05) | probably_damaging(0.963) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
S100A12 | SNV | Missense_Mutation | | c.124N>A | p.Ala42Thr | p.A42T | P80511 | protein_coding | tolerated(0.09) | benign(0.133) | TCGA-BS-A0TJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
S100A12 | SNV | Missense_Mutation | novel | c.260A>C | p.Tyr87Ser | p.Y87S | P80511 | protein_coding | deleterious(0.04) | benign(0) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
S100A12 | SNV | Missense_Mutation | | c.68N>A | p.Gly23Glu | p.G23E | P80511 | protein_coding | deleterious(0.03) | probably_damaging(0.957) | TCGA-95-7562-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | SD |
S100A12 | SNV | Missense_Mutation | novel | c.232G>T | p.Val78Leu | p.V78L | P80511 | protein_coding | tolerated(0.15) | benign(0) | TCGA-90-7964-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
S100A12 | SNV | Missense_Mutation | novel | c.55T>A | p.Ser19Thr | p.S19T | P80511 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-P3-A6T4-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |